{"id":63129,"date":"2026-04-14T21:25:12","date_gmt":"2026-04-14T13:25:12","guid":{"rendered":"https:\/\/flcube.com\/?p=63129"},"modified":"2026-04-14T21:25:13","modified_gmt":"2026-04-14T13:25:13","slug":"chinas-nhsa-selects-31-innovative-drugs-for-historic-reference-drug-pre-communication-program","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63129","title":{"rendered":"China&#8217;s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program"},"content":{"rendered":"\n<p>The <strong>National Healthcare Security Administration (NHSA)<\/strong> has published the inaugural list of <strong>31 innovative drugs<\/strong> eligible for China&#8217;s first-ever <strong>reference drug pre-communication initiative<\/strong>, as outlined in its February 2026 policy document. The program aims to establish early pricing and reimbursement dialogue with pharmaceutical companies ahead of formal National Reimbursement Drug List (NRDL) negotiations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-program-framework\">Program Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Initiative<\/strong><\/td><td>Reference Drug Pre-Communication Program<\/td><\/tr><tr><td><strong>Administering Agency<\/strong><\/td><td>National Healthcare Security Administration (NHSA)<\/td><\/tr><tr><td><strong>First Batch Drugs<\/strong><\/td><td>31 Category 1 innovative medicines<\/td><\/tr><tr><td><strong>Application Deadline<\/strong><\/td><td>End of March 2026<\/td><\/tr><tr><td><strong>Implementation Timing<\/strong><\/td><td>To be initiated &#8220;at an appropriate time&#8221; per NHSA guidance<\/td><\/tr><tr><td><strong>Eligibility Criteria<\/strong><\/td><td>Three conditions based on approval status and timeline<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-eligibility-conditions\">Eligibility Conditions<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-condition-1-24-drugs\">Condition 1 (24 drugs)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Approved for marketing by China&#8217;s national drug regulatory authority within five years (after January 1, 2021)<\/li>\n\n\n\n<li>Represents majority of submissions including products from Sanofi, GSK, Pfizer, Novartis, and Merck<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-condition-2-1-drug\">Condition 2 (1 drug)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Approved within five years with major changes in indications\/functions<\/li>\n\n\n\n<li>Requires specific approval documents for such changes<\/li>\n\n\n\n<li>Only <strong>Emicizumab<\/strong> (Roche) qualifies under this category<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-condition-3-6-drugs\">Condition 3 (6 drugs)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Not yet approved but marketing applications accepted and passed technical review<\/li>\n\n\n\n<li>Includes candidates from domestic innovators like Changshan ConjuChem, Hangzhou Aomo, and Innovent Biologics<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-notable-submissions-by-company\">Notable Submissions by Company<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-multinational-pharmaceutical-companies\">Multinational Pharmaceutical Companies<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sanofi:<\/strong> Aficamten (Condition 1)<\/li>\n\n\n\n<li><strong>Roche:<\/strong> Emicizumab (Condition 2)<\/li>\n\n\n\n<li><strong>GSK:<\/strong> Depemokimab (Condition 1)<\/li>\n\n\n\n<li><strong>Pfizer:<\/strong> Marstacimab (Condition 1)<\/li>\n\n\n\n<li><strong>Novartis:<\/strong> Remibrutinib, Atrasentan (both Condition 1)<\/li>\n\n\n\n<li><strong>Merck Serono:<\/strong> Pimicotinib (Condition 1)<\/li>\n\n\n\n<li><strong>Boehringer Ingelheim:<\/strong> Nerandomilast, Zongertinib (both Condition 1)<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-leading-chinese-biopharmaceutical-companies\">Leading Chinese Biopharmaceutical Companies<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovent Biologics:<\/strong> Mazdutide (Condition 3), Picankibart (Condition 1)<\/li>\n\n\n\n<li><strong>Chia Tai Tianqing:<\/strong> Culmerciclib, Rovadicitinib (both Condition 1)<\/li>\n\n\n\n<li><strong>Suzhou Ascentage Pharma:<\/strong> Lisaftoclax (Condition 1)<\/li>\n\n\n\n<li><strong>Jiangsu Hengrui:<\/strong> Zeprumetostat (Condition 1)<\/li>\n\n\n\n<li><strong>Hangzhou Sciwind Biosciences:<\/strong> Ecnoglutide (Condition 1)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-pharmaceutical-companies\">For Pharmaceutical Companies<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Early Engagement:<\/strong> Opportunity to influence pricing expectations before formal NRDL negotiations<\/li>\n\n\n\n<li><strong>Market Access Acceleration:<\/strong> Potential for faster reimbursement decisions through proactive dialogue<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> First-mover advantage in establishing value propositions with payers<\/li>\n\n\n\n<li><strong>Risk Mitigation:<\/strong> Reduced uncertainty around reimbursement timelines and pricing levels<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-china-s-healthcare-system\">For China&#8217;s Healthcare System<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Budget Impact Management:<\/strong> Enhanced ability to forecast and manage pharmaceutical expenditure<\/li>\n\n\n\n<li><strong>Innovation Incentives:<\/strong> Structured pathway for premium pricing of truly innovative therapies<\/li>\n\n\n\n<li><strong>Patient Access:<\/strong> Improved timeline predictability for accessing cutting-edge treatments<\/li>\n\n\n\n<li><strong>International Alignment:<\/strong> Brings China closer to global health technology assessment practices<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NRDL Significance:<\/strong> Inclusion in China&#8217;s National Reimbursement Drug List can increase sales by 300-500% within first year<\/li>\n\n\n\n<li><strong>Pricing Pressure:<\/strong> Average price reductions of 50-60% in recent NRDL negotiations create need for early strategic planning<\/li>\n\n\n\n<li><strong>Innovation Focus:<\/strong> All 31 drugs are Category 1 (first-in-class or best-in-class) innovations, reflecting NHSA&#8217;s priority on high-value therapies<\/li>\n\n\n\n<li><strong>Domestic vs. International:<\/strong> Balanced representation demonstrates China&#8217;s dual commitment to supporting domestic innovation while maintaining access to global breakthroughs<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-next-steps\">Next Steps<\/h2>\n\n\n\n<p>The NHSA will initiate pre-communication sessions &#8220;at an appropriate time,&#8221; likely following internal prioritization based on clinical urgency, budget impact, and therapeutic area gaps. Companies should prepare comprehensive health economic dossiers and value-based pricing proposals.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory processes, market access strategies, and commercial expectations related to China&#8217;s reference drug pre-communication initiative. Actual outcomes may differ due to policy changes, competitive dynamics, and evolving healthcare priorities.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The National Healthcare Security Administration (NHSA) has published the inaugural list of 31 innovative drugs&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[200,390,661,184,2586,198,120,67,140,309,163,147,822],"class_list":["post-63129","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-ascentage-pharma","tag-boehringer-ingelheim","tag-chia-tai-tianqing-pharmaceutical","tag-gsk","tag-hengrui-pharmaceuticals","tag-innovent-biologics","tag-merck","tag-nhsa-prev-smia","tag-novartis","tag-pfizer","tag-roche","tag-sanofi","tag-sciwind-biosciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China&#039;s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The National Healthcare Security Administration (NHSA) has published the inaugural list of 31 innovative drugs eligible for China&#039;s first-ever reference drug pre-communication initiative, as outlined in its February 2026 policy document. The program aims to establish early pricing and reimbursement dialogue with pharmaceutical companies ahead of formal National Reimbursement Drug List (NRDL) negotiations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63129\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China&#039;s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program\" \/>\n<meta property=\"og:description\" content=\"The National Healthcare Security Administration (NHSA) has published the inaugural list of 31 innovative drugs eligible for China&#039;s first-ever reference drug pre-communication initiative, as outlined in its February 2026 policy document. The program aims to establish early pricing and reimbursement dialogue with pharmaceutical companies ahead of formal National Reimbursement Drug List (NRDL) negotiations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63129\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-14T13:25:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-14T13:25:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63129#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63129\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China&#8217;s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program\",\"datePublished\":\"2026-04-14T13:25:12+00:00\",\"dateModified\":\"2026-04-14T13:25:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63129\"},\"wordCount\":510,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ascentage Pharma\",\"Boehringer Ingelheim\",\"Chia Tai Tianqing Pharmaceutical\",\"GSK\",\"Hengrui Pharmaceuticals\",\"Innovent Biologics\",\"Merck\",\"NHSA (prev. SMIA)\",\"Novartis\",\"Pfizer\",\"Roche\",\"Sanofi\",\"Sciwind Biosciences\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63129#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63129\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63129\",\"name\":\"China's NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-14T13:25:12+00:00\",\"dateModified\":\"2026-04-14T13:25:13+00:00\",\"description\":\"The National Healthcare Security Administration (NHSA) has published the inaugural list of 31 innovative drugs eligible for China's first-ever reference drug pre-communication initiative, as outlined in its February 2026 policy document. The program aims to establish early pricing and reimbursement dialogue with pharmaceutical companies ahead of formal National Reimbursement Drug List (NRDL) negotiations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63129#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63129\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63129#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China&#8217;s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China's NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program - Insight, China&#039;s Pharmaceutical Industry","description":"The National Healthcare Security Administration (NHSA) has published the inaugural list of 31 innovative drugs eligible for China's first-ever reference drug pre-communication initiative, as outlined in its February 2026 policy document. The program aims to establish early pricing and reimbursement dialogue with pharmaceutical companies ahead of formal National Reimbursement Drug List (NRDL) negotiations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63129","og_locale":"en_US","og_type":"article","og_title":"China's NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program","og_description":"The National Healthcare Security Administration (NHSA) has published the inaugural list of 31 innovative drugs eligible for China's first-ever reference drug pre-communication initiative, as outlined in its February 2026 policy document. The program aims to establish early pricing and reimbursement dialogue with pharmaceutical companies ahead of formal National Reimbursement Drug List (NRDL) negotiations.","og_url":"https:\/\/flcube.com\/?p=63129","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-14T13:25:12+00:00","article_modified_time":"2026-04-14T13:25:13+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63129#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63129"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China&#8217;s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program","datePublished":"2026-04-14T13:25:12+00:00","dateModified":"2026-04-14T13:25:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63129"},"wordCount":510,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ascentage Pharma","Boehringer Ingelheim","Chia Tai Tianqing Pharmaceutical","GSK","Hengrui Pharmaceuticals","Innovent Biologics","Merck","NHSA (prev. SMIA)","Novartis","Pfizer","Roche","Sanofi","Sciwind Biosciences"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63129#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63129","url":"https:\/\/flcube.com\/?p=63129","name":"China's NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-14T13:25:12+00:00","dateModified":"2026-04-14T13:25:13+00:00","description":"The National Healthcare Security Administration (NHSA) has published the inaugural list of 31 innovative drugs eligible for China's first-ever reference drug pre-communication initiative, as outlined in its February 2026 policy document. The program aims to establish early pricing and reimbursement dialogue with pharmaceutical companies ahead of formal National Reimbursement Drug List (NRDL) negotiations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63129#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63129"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63129#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China&#8217;s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63129","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63129"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63129\/revisions"}],"predecessor-version":[{"id":63132,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63129\/revisions\/63132"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63129"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63129"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63129"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}